OBJECTIVE: To compare the cognitive and psychiatric status of patients with Parkinson's disease related to the G2019S and the R1441G mutations of the LRRK2 gene (LRRK2-PD) and idiopathic Parkinson's disease (iPD) patients. METHODS: We examined cognition and psychiatric symptoms in 27 patients with LRRK2-PD (12 G2019S and 15 R1441G) and 27 iPD patients. RESULTS: The groups were similar in age, education, disease duration, levodopa equivalent daily dose, and Unified Parkinson's Disease Rating Scale (UPDRS) II-IV; however, the LRRK2-PD showed less impairment on UPDRS-I (2.0 ± 1.7 vs. 4.2 ± 2.8, p = 0.003). The LRRK2-PD presented less frequent subjective cognitive complaints (18.5% vs. 63.0%, p = 0.002), and mild cognitive impairment or dementia (25.9% vs. 59.2%, p = 0.027). They also showed less impairment on scales for general cognition (Mattis dementia rating scale 131.2 ± 10.9 vs. 119 ± 24.0, p = 0.022), episodic verbal memory (Rey's auditory verbal learning test, immediate recall 39.2 ± 9.5 vs. 27.6 ± 12.8 p < 0.001, delayed recall 7.2 ± 3.7 vs. 4.7 ± 4.0 p = 0.022), and the Neuropsychiatric Inventory (9.7 ± 9.2 vs. 20.5 ± 14.3, p = 0.004, significant differences for apathy and hallucinations). The LRRK2-PD subjects were less frequently treated with antipsychotic medication (0% vs. 25.9%, p = 0.010). There were no significant differences between G2019S and R1441G mutation carriers. CONCLUSIONS: Mutations of the LRRK2 gene might cause PD associated with less cognitive and neuropsychiatric impairment as compared to iPD.
OBJECTIVE: To compare the cognitive and psychiatric status of patients with Parkinson's disease related to the G2019S and the R1441G mutations of the LRRK2 gene (LRRK2-PD) and idiopathic Parkinson's disease (iPD) patients. METHODS: We examined cognition and psychiatric symptoms in 27 patients with LRRK2-PD (12 G2019S and 15 R1441G) and 27 iPD patients. RESULTS: The groups were similar in age, education, disease duration, levodopa equivalent daily dose, and Unified Parkinson's Disease Rating Scale (UPDRS) II-IV; however, the LRRK2-PD showed less impairment on UPDRS-I (2.0 ± 1.7 vs. 4.2 ± 2.8, p = 0.003). The LRRK2-PD presented less frequent subjective cognitive complaints (18.5% vs. 63.0%, p = 0.002), and mild cognitive impairment or dementia (25.9% vs. 59.2%, p = 0.027). They also showed less impairment on scales for general cognition (Mattis dementia rating scale 131.2 ± 10.9 vs. 119 ± 24.0, p = 0.022), episodic verbal memory (Rey's auditory verbal learning test, immediate recall 39.2 ± 9.5 vs. 27.6 ± 12.8 p < 0.001, delayed recall 7.2 ± 3.7 vs. 4.7 ± 4.0 p = 0.022), and the Neuropsychiatric Inventory (9.7 ± 9.2 vs. 20.5 ± 14.3, p = 0.004, significant differences for apathy and hallucinations). The LRRK2-PD subjects were less frequently treated with antipsychotic medication (0% vs. 25.9%, p = 0.010). There were no significant differences between G2019S and R1441G mutation carriers. CONCLUSIONS: Mutations of the LRRK2 gene might cause PD associated with less cognitive and neuropsychiatric impairment as compared to iPD.
Authors: Steven A Gunzler; David E Riley; Shu G Chen; Curtis M Tatsuoka; William M Johnson; John J Mieyal; Ellen M Walter; Christina M Whitney; I Jung Feng; Harry Owusu-Dapaah; Shivam O Mittal; Amy L Wilson-Delfosse Journal: J Neurol Sci Date: 2018-03-17 Impact factor: 3.181
Authors: Ignacio F Mata; Marie Y Davis; Alexis N Lopez; Michael O Dorschner; Erica Martinez; Dora Yearout; Brenna A Cholerton; Shu-Ching Hu; Karen L Edwards; Thomas D Bird; Cyrus P Zabetian Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-04-25 Impact factor: 3.568
Authors: Tanya Simuni; Michael C Brumm; Liz Uribe; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; Roy N Alcalay; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Kelly Nudelman; Duygu Tosun-Turgut; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha Hutten; Susan Bressman; Kenneth Marek Journal: Mov Disord Date: 2020-02-19 Impact factor: 10.338
Authors: Erin K Donahue; Amjad Murdos; Michael W Jakowec; Nasim Sheikh-Bahaei; Arthur W Toga; Giselle M Petzinger; Farshid Sepehrband Journal: Mov Disord Date: 2021-01-20 Impact factor: 10.338
Authors: Sokhna M S Yakhine-Diop; Mario Rodríguez-Arribas; Saray Canales-Cortés; Guadalupe Martínez-Chacón; Elisabet Uribe-Carretero; Mercedes Blanco-Benítez; Gema Duque-González; Marta Paredes-Barquero; Eva Alegre-Cortés; Vicente Climent; Ana Aiastui; Adolfo López de Munain; José M Bravo-San Pedro; Mireia Niso-Santano; José M Fuentes; Rosa A González-Polo Journal: Cell Biol Toxicol Date: 2021-05-31 Impact factor: 6.819
Authors: Max Sloan; Javier Alegre-Abarrategui; Dawid Potgieter; Anna-Kristin Kaufmann; Richard Exley; Thierry Deltheil; Sarah Threlfell; Natalie Connor-Robson; Katherine Brimblecombe; Rebecca Wallings; Milena Cioroch; David M Bannerman; J Paul Bolam; Peter J Magill; Stephanie J Cragg; Paul D Dodson; Richard Wade-Martins Journal: Hum Mol Genet Date: 2016-01-06 Impact factor: 6.150